BiotechTube
Nami Therapeutics

Nami Therapeutics

San Diego, United States· Est.
namitherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20M

Overview

Nami Therapeutics is a private, pre-clinical stage biotech developing targeted radiotherapeutics for cancer. The company's core technology involves engineered nanocarriers designed to deliver therapeutic payloads precisely to tumors, aiming to improve efficacy and reduce off-target effects. While the pipeline is described as robust and dynamic, specific programs and indications are not publicly disclosed on the website. The company appears to be in a foundational growth phase, building its team and intellectual property portfolio.

Oncology

Technology Platform

Proprietary nanocarriers designed for precise and targeted delivery of radiotherapeutic payloads to tumors.

Funding History

2
Total raised:$20M
Series A$15M
Seed$5M

Opportunities

The company is operating in the high-growth radiopharmaceuticals market, which is validated by recent commercial successes.
Its nanocarrier platform, if effective, could address key limitations in tumor targeting and therapeutic index for a range of cancers.
Strategic partnerships with larger pharmaceutical companies present a significant opportunity for funding and development.

Risk Factors

As an early-stage company, Nami faces high technical risk with an unproven platform, significant financing risk to fund development, and intense competition from established players in the radiopharmaceutical space.
The lack of disclosed pipeline specifics makes it difficult to assess program viability and differentiation.

Competitive Landscape

Nami competes in the rapidly consolidating radiopharmaceutical sector against giants like Novartis, Bayer, and Eli Lilly, as well as numerous biotechs such as RayzeBio, Fusion Pharmaceuticals, and Aktis Oncology. Differentiation will require demonstrating superior targeting, safety, or applicability to hard-to-treat tumors compared to existing antibody- or small molecule-based radiopharmaceuticals.

More companies in United States →